FDA gives a nod to Turalio as the first treatment for rare joint tumor

Daiichi Sankyoâs Turalio becomes the first FDA-approved TGCT treatment, after receiving breakthrough therapy, priority review and orphan drug designation.

Original Article: FDA gives a nod to Turalio as the first treatment for rare joint tumor

More From BioPortfolio on "FDA gives a nod to Turalio as the first treatment for rare joint tumor"